Orchid Pharma Q3 FY26: net loss, revenue down 16 percent YoY, qualified auditor view

Revenue declinedNet loss reportedExceptional itemQualified audit opinionResults View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.7%Reaction day

₹690.00

prior close

₹679.45

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-1.2% vs market

Pharmaceuticals peers, median of 157sector-0.6%-1.0% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.1

10m

-2.0

15m

-1.8

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.7-0.5-1.2-0.6-1.0

Next day

-2.9-2.0-0.9-1.4-1.5

-4.3-2.7-1.7-2.1-2.2

-4.2-1.7-2.5-1.6-2.6

-4.0-1.4-2.6-1.6-2.5

-2.9-2.8-0.1-2.4-0.5

-3.6-2.8-0.8-2.9-0.7

15d

-26.4-8.4-18.0-6.3-20.1

-21.8-9.1-12.7-6.5-15.3

-20.7-4.0-16.7-3.3-17.4

+2.1+2.6-0.5+0.7+1.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Orchid Pharma Q3 FY26: standalone net loss of Rs 582.43 lakhs vs profit of Rs 2,390.63 lakhs YoY. Consolidated loss Rs 1,261.35 lakhs. Nine-month revenue fell about 16 percent to Rs 57,372 lakhs from Rs 68,444.72 lakhs. Nine-month standalone PAT dropped sharply to Rs 1,460.42 lakhs from Rs 7,863.47 lakhs. An exceptional charge of Rs 711.27 lakhs was taken for the new labour codes impact on employee benefits. Auditor issued a qualified conclusion on the consolidated review due to unreviewed subsidiary financials. NCLT hearing on Dhanuka Laboratories amalgamation scheduled for March 2, 2026.

Likely market impact

Revenue decline, quarterly losses, and labour code charge weigh on sentiment, but Dhanuka merger progress and auditor qualification are key watch items.